How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery?

We reported nodal and breast downstaging rates with NET, and compared axillary response rates following NET and neoadjuvant chemotherapy (NAC).MethodsConsecutive stage I –III breast cancer patients treated with NET and surgery from January 2009 to December 2019 were identified from a prospectively maintained database. Nodal pCR rates were compared between biopsy-proven node-positive patients treated with NET, and HR+/HER2- patients treated with NAC from November 2 013 to July 2019.Results127 cancers treated with NET and 338 with NAC were included. NET recipients were older, more likely to have lobular and lower-grade tumors, and higher HR expression. With NET, the nodal pCR rate was 11% (4/38) of biopsy-proven cases, and the breast pCR rate was 1.6% (2/126). Nodal-dowstaging rates with NET and NAC were not significantly different (11% vs 18%;P = 0.37). Patients achieving nodal pCR with NET versus NAC were older (median age 70 vs 50,P = 0.004) and had greater progesterone receptor (PR) expression (85% vs 13%,P = 0.031), respectively. Of patients not candidates for BCS due to a large tumor relative to breast size, 36/47 (77%) became BCS-eligible with NET (median PR expression 55% vs 5% in those remaining ineligible,P 
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Nat Rev Clin Oncol. 2021 Sep 24. doi: 10.1038/s41571-021-00558-1. Online ahead of print.ABSTRACTProtein tyrosine kinases of the human epidermal growth factor receptor family, including EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung, breast and gastroesophageal cancers, and are of relevance for the treatment of various other malignancies (particularly colorectal cancer). Classic activating EGFR exon 19 deletions and exon 21 mutations, and HER2 amplification and/or overexpression, are predictive of response to matched molecularly targeted therapies, translating into favourable objective r...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
Breast Cancer. 2021 Sep 25. doi: 10.1007/s12282-021-01299-w. Online ahead of print.NO ABSTRACTPMID:34562259 | DOI:10.1007/s12282-021-01299-w
Source: Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
Progression - free survival longer with T - DXd versus T - DM1 for HER2+ metastatic breast cancer previously treated with trastuzumab and taxane
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Conference News, Source Type: news
Pathol Res Pract. 2021 Sep 22;227:153619. doi: 10.1016/j.prp.2021.153619. Online ahead of print.ABSTRACTBACKGROUND: HER2 was a recognized oncogene that promoted the development and metastasis of breast cancer, but its positive expression rate in invasive ductal carcinoma (IDC) was much lower than that in ductal carcinoma in situ (DCIS). The correlation between the occurrence and development of breast cancer and the amplification and overexpression of HER2 gene alone was still controversial. 14-3-3ζ had a strong protein binding ability and a variety of functions, mainly through the interaction with other proteins to ex...
Source: Pathology, Research and Practice - Category: Pathology Authors: Source Type: research
In conclusion, we demonstrate that circ_0001598/miR-1184/PD-L1 signaling plays a crucial role in the regulation of BC progression and trastuzumab-resistance phonotypes, which suggests that circ_0001598 may be a molecular target to treat HER2-positive BC patients.PMID:34559381 | DOI:10.1007/s12026-021-09237-w
Source: Cell Research - Category: Cytology Authors: Source Type: research
Conclusions: This study demonstrates that the combination of locoregional breast RT with dual HER2 blockade by Pertu/Trastu was very well tolerated, suggesting that RT can be safely administered to patients with HER2-positive breast cancer.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
zo Castagnoli HER2 overexpression/amplification occurs in 15–20% of breast cancers (BCs) and identifies a highly aggressive BC subtype. Recent clinical progress has increased the cure rates of limited-stage HER2-positive BC and significantly prolonged overall survival in patients with advanced disease; however, drug resistance and tumor recurrence remain major concerns. Therefore, there is an urgent need to increase knowledge regarding HER2 biology and implement available treatments. Cancer stem cells (CSCs) represent a subset of malignant cells capable of unlimited self-renewal and differentiation and are mainly...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
In conclusion, we demonstrate that circ_0001598/miR-1184/PD-L1 signaling plays a crucial role in the regulation of BC progression and trastuzumab-resistance phonotypes, which suggests that circ_0001598 may be a molecular target to treat HER2-positive BC patients.
Source: Immunologic Research - Category: Allergy & Immunology Source Type: research
Condition:   Locally Advanced or Metastatic Breast Cancer Interventions:   Drug: GB491+ Fulvestrant;   Drug: Placebo+Fulvestrant Sponsor:   Genor Biopharma Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Source: Vascular Health and Risk Management - Category: Cardiology Tags: Breast Cancer: Targets and Therapy Source Type: research
More News: Breast Cancer | Breast Conservation Surgery | Breast Surgery | Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | Endocrine Therapy | HER2 | Hormones | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy